Conavi Medical reports fiscal third-quarter 2026 results showing a net loss of $6.3 million, compared with a $3.6 million net loss in fiscal third-quarter 2025. The company also reports continued investment in research and development, with R&D expenses of $4.4 million in the quarter, up from $3.2 million a year earlier.
Financial Post also says Conavi Medical ends fiscal Q3 2026 with $0.9 million in cash and cash equivalents, down from $5.8 million at the end of fiscal Q4 2025. The outlet notes that, on August 12, 2026, the company closes with respect to an unspecified action (as described only partially in the provided text).
Seeking Alpha’s item is listed as “Conavi Medical Corp. reports Q3 results,” but no additional financial figures or details are included in the provided excerpt. As a result, the available information across outlets largely overlaps on the existence of Q3 results, with specific numerical details coming from the Financial Post source.
